Sumitomo Mitsui Trust Group Inc. Trims Stock Holdings in Zoetis Inc. $ZTS

Sumitomo Mitsui Trust Group Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 12.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 963,773 shares of the company’s stock after selling 132,499 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Zoetis were worth $113,928,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis in the fourth quarter valued at $25,000. Prosperity Bancshares Inc purchased a new stake in Zoetis during the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the 3rd quarter worth about $31,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the 4th quarter worth about $30,000. Finally, Elyxium Wealth LLC purchased a new position in Zoetis during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZTS. Stifel Nicolaus decreased their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Finally, Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $123.46.

Zoetis Price Performance

ZTS stock traded up $0.41 during midday trading on Friday, reaching $75.49. The company had a trading volume of 5,157,373 shares, compared to its average volume of 6,410,874. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $160.48. The company has a market capitalization of $31.65 billion, a P/E ratio of 12.52, a P/E/G ratio of 1.17 and a beta of 0.75. The firm has a 50-day moving average price of $79.96 and a 200-day moving average price of $107.76.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter last year, the business posted $1.48 EPS. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Insiders Place Their Bets

In other news, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,650 shares of company stock valued at $886,384 over the last 90 days. Insiders own 0.22% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Glancy Prongay, Bragar Eagel & Squire, The Gross Law Firm, Kessler Topaz, Schall, Howard G. Smith, and Bernstein Liebhard, are urging investors who bought ZTS shares during the class period to contact them before the July 27 lead plaintiff deadline.
• Negative Sentiment: A class action lawsuit has been filed against Zoetis and certain officers, with allegations of material misstatements and/or omissions tied to product adoption, which may increase legal costs and pressure the stock. Article Title

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.